MEIP
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
33.33M
GET INTRADAY SIGNALS
MEIP Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
48 days until earnings call
+Compare
MEIP
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
33.33M

MEIP MEI Pharma Forecast, Technical & Fundamental Analysis

a mfactures pharmaceuticals products

Industry Biotechnology
GET INTRADAY SIGNALS
MEIP Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 23, 2023

MEIP's RSI Indicator ascending out of oversold territory

The RSI Oscillator for MEIP moved out of oversold territory on March 02, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 30 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on March 10, 2023. You may want to consider a long position or call options on MEIP as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MEIP just turned positive on March 13, 2023. Looking at past instances where MEIP's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MEIP advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .

MEIP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

MEIP moved below its 50-day moving average on February 23, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MEIP crossed bearishly below the 50-day moving average on February 24, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEIP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.689) is normal, around the industry mean (21.708). P/E Ratio (0.000) is within average values for comparable stocks, (125.534). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.749). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (0.532) is also within normal values, averaging (303.071).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MEIP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MEIP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.96B. The market cap for tickers in the group ranges from 160 to 331.75B. NONOF holds the highest valuation in this group at 331.75B. The lowest valued company is CDXI at 160.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 0%. CALC experienced the highest price growth at 1,040%, while MMIRF experienced the biggest fall at -92%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was -64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: -2 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I. Advisor
published Earnings

MEIP is expected to report earnings to fall 254.13% to -12 cents per share on May 11

MEI Pharma MEIP Stock Earnings Reports
Q1'23
Est.
$-0.12
Q4'22
Beat
by $0.22
Q3'22
Beat
by $0.05
Q2'22
Missed
by $0.02
Q1'22
Beat
by $0.11
The last earnings report on February 09 showed earnings per share of 7 cents, beating the estimate of -14 cents. With 2.21M shares outstanding, the current market capitalization sits at 33.33M.
AI
A.I. Advisor
published General Information

General Information

a mfactures pharmaceuticals products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
11455 El Camino Real
Phone
+1 858 369-7100
Employees
102
Web
https://www.meipharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ICLK3.310.11
+3.44%
iClick Interactive Asia Group Limited
HSKA89.200.51
+0.58%
Heska Corp
HT5.920.02
+0.34%
Hersha Hospitality Trust Priority
SGEN198.10-0.27
-0.14%
Seagen
PINC31.35-0.25
-0.79%
Premier

MEIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEIP has been loosely correlated with ICVX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MEIP jumps, then ICVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEIP
1D Price
Change %
MEIP100%
-0.04%
ICVX - MEIP
51%
Loosely correlated
-1.28%
VIR - MEIP
36%
Loosely correlated
-0.36%
GOSS - MEIP
31%
Poorly correlated
-3.60%
OCGN - MEIP
30%
Poorly correlated
-3.38%
VXRT - MEIP
29%
Poorly correlated
+1.51%
More

Groups containing MEIP

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEIP
1D Price
Change %
MEIP100%
-0.04%
pharmaceuticals
(undefined stocks)
22%
Poorly correlated
+0.01%